Confo Therapeutics Overview

  • Year Founded
  • 2015

Year Founded

  • Status
  • Private

  • Employees
  • 82

Employees

  • Latest Deal Type
  • Grant

  • Latest Deal Amount
  • $1.17M

  • Investors
  • 19

Confo Therapeutics General Information

Description

Developer of a drug discovery platform intended to identify medicines targeting G protein-coupled receptors. The company utilizes proprietary single-domain antibodies to stabilize functional receptor conformations, enabling the discovery of small molecules and antibodies for metabolic, endocrine, and chronic pain conditions, enabling pharmaceutical partners to access previously inaccessible therapeutic targets.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Technologiepark-Zwijnaarde 30
  • Zwijnaarde
  • 9052 Ghent
  • Belgium
+32 09
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • Technologiepark-Zwijnaarde 30
  • Zwijnaarde
  • 9052 Ghent
  • Belgium
+32 09

Confo Therapeutics Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Confo Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
12. Grant 08-Oct-2025 $1.17M Completed Clinical Trials - Phase 1
11. Later Stage VC (Series B) 26-Jul-2024 Completed Clinical Trials - Phase 1
10. Grant 28-Mar-2024 Completed Clinical Trials - Phase 1
9. Grant 28-Jun-2022 Completed Clinical Trials - Phase 1
8. Grant 30-Mar-2021 Completed Clinical Trials - Phase 1
7. Grant 20-Jun-2019 Completed Clinical Trials - Phase 1
6. Early Stage VC (Series A) 01-May-2019 Completed Clinical Trials - Phase 1
5. Grant 20-Feb-2018 Completed Clinical Trials - Phase 1
4. Grant 01-Feb-2017 $2.74M $7.28M Completed Clinical Trials - Phase 1
3. Early Stage VC 01-Feb-2016 $7.28M $7.28M Completed Clinical Trials - Phase 1
To view Confo Therapeutics’s complete valuation and funding history, request access »

Confo Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Class C
Class C
Class B2 4,917,475 $6.5 $6.5 1x $6.5 38.45%
Class B 800,000 $4.33 $4.33 1x $4.33 6.26%
To view Confo Therapeutics’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Confo Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of a drug discovery platform intended to identify medicines targeting G protein-coupled receptors. The company
Drug Discovery
Ghent, Belgium
82 As of 2026

Cambridge, MA
 

South San Francisco, CA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Confo Therapeutics Competitors (93)

One of Confo Therapeutics’s 93 competitors is Marengo Therapeutics, a Venture Capital-Backed company based in Cambridge, MA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Marengo Therapeutics Venture Capital-Backed Cambridge, MA
CytomX Therapeutics Formerly VC-backed South San Francisco, CA
Alzheon Venture Capital-Backed Framingham, MA
Lisata Therapeutics Corporation Basking Ridge, NJ
Biomunex Pharmaceuticals Venture Capital-Backed Paris, France
You’re viewing 5 of 93 competitors. Get the full list »

Confo Therapeutics Patents

Confo Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-4605077-A1 Amino acid sequences directed against the melanocortin 4 receptor and polypeptides comprising the same for the treatment of mc4r-related diseases and disorders Pending 18-Oct-2022
US-20260103529-A1 Amino acid sequences directed against the melanocortin 4 receptor and polypeptides comprising the same for the treatment of mc4r-related diseases and disorders Pending 18-Oct-2022
WO-2024083843-A1 Amino acid sequences directed against the melanocortin 4 receptor and polypeptides comprising the same for the treatment of mc4r-related diseases and disorders Inactive 18-Oct-2022
AU-2022318349-A1 Compounds for the treatment of pain, in particular neuropathic pain, and/or other diseases or disorders that are associated with at2r and/or at2r mediated signaling Active 30-Jul-2021
AU-2022318349-B2 Compounds for the treatment of pain, in particular neuropathic pain, and/or other diseases or disorders that are associated with at2r and/or at2r mediated signaling Active 30-Jul-2021 C07D403/14
To view Confo Therapeutics’s complete patent history, request access »

Confo Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Confo Therapeutics Investors (19)

Investor Name Investor Type Holding Investor Since Participating Rounds
Ackermans & van Haaren Growth/Expansion Minority
Driehaus Capital Management Corporation Minority
Quest For Growth Asset Manager Minority
BioGeneration Ventures Venture Capital Minority
Fund+ Venture Capital Minority
You’re viewing 5 of 19 investors. Get the full list »

Confo Therapeutics FAQs

  • When was Confo Therapeutics founded?

    Confo Therapeutics was founded in 2015.

  • Where is Confo Therapeutics headquartered?

    Confo Therapeutics is headquartered in Ghent, Belgium.

  • What is the size of Confo Therapeutics?

    Confo Therapeutics has 82 total employees.

  • What industry is Confo Therapeutics in?

    Confo Therapeutics’s primary industry is Drug Discovery.

  • Is Confo Therapeutics a private or public company?

    Confo Therapeutics is a Private company.

  • What is Confo Therapeutics’s current revenue?

    The current revenue for Confo Therapeutics is .

  • How much funding has Confo Therapeutics raised over time?

    Confo Therapeutics has raised $105M.

  • Who are Confo Therapeutics’s investors?

    Ackermans & van Haaren, Driehaus Capital Management, Quest For Growth, BioGeneration Ventures, and Fund+ are 5 of 19 investors who have invested in Confo Therapeutics.

  • Who are Confo Therapeutics’s competitors?

    Marengo Therapeutics, CytomX Therapeutics, Alzheon, Lisata Therapeutics, and Biomunex Pharmaceuticals are some of the 93 competitors of Confo Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process